Sana Capital Expenditures vs Stock Based Compensation Analysis

SANA Stock

USD 1.91 0.02 1.06%

Sana Biotechnology financial indicator trend analysis is much more than just breaking down Sana Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sana Biotechnology is a good investment. Please check the relationship between Sana Biotechnology Capital Expenditures and its Stock Based Compensation accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.

Capital Expenditures vs Stock Based Compensation

Capital Expenditures vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sana Biotechnology Capital Expenditures account and Stock Based Compensation. At this time, the significance of the direction appears to have strong relationship.

The correlation between Sana Biotechnology's Capital Expenditures and Stock Based Compensation is 0.68. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Sana Biotechnology, assuming nothing else is changed. The correlation between historical values of Sana Biotechnology's Capital Expenditures and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Sana Biotechnology are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Capital Expenditures i.e., Sana Biotechnology's Capital Expenditures and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

0.68

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Sana Biotechnology to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Sana Biotechnology operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Sana Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sana Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.As of December 17, 2024, Selling General Administrative is expected to decline to about 46.5 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 30.1 M

	2021	2022	2023	2024 (projected)
Total Operating Expenses	356.9M	272.6M	294.9M	249.3M
Cost Of Revenue	17.9M	27.7M	30.9M	16.6M

Total Operating Expenses Cost Of Revenue

Sana Biotechnology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital	Common Stock
Total Assets		0.93	0.92	0.58	0.96	0.36	0.97	-0.55	-0.8	0.79	0.85	0.99	0.92	0.87	0.97	-0.22	0.61	0.93	0.85	0.69	0.58	0.94	0.99	1.0	0.98	0.81
Other Current Liab	0.93		1.0	0.79	0.81	0.61	0.94	-0.27	-0.86	0.81	0.63	0.91	0.97	0.94	0.89	-0.18	0.31	0.94	0.9	0.42	0.79	0.95	0.92	0.92	0.88	0.94
Total Current Liabilities	0.92	1.0		0.78	0.81	0.6	0.95	-0.28	-0.87	0.83	0.64	0.91	0.96	0.93	0.89	-0.15	0.32	0.94	0.92	0.42	0.78	0.96	0.92	0.91	0.88	0.94
Total Stockholder Equity	0.58	0.79	0.78		0.38	0.92	0.59	0.2	-0.6	0.52	0.13	0.57	0.84	0.86	0.62	-0.36	-0.29	0.56	0.69	-0.18	1.0	0.63	0.58	0.58	0.51	0.83
Other Liab	0.96	0.81	0.81	0.38		0.19	0.93	-0.69	-0.77	0.81	0.93	0.96	0.81	0.78	0.92	-0.14	0.76	0.86	0.82	0.82	0.38	0.9	0.94	0.96	0.95	0.71
Net Tangible Assets	0.36	0.61	0.6	0.92	0.19		0.42	0.42	-0.59	0.46	-0.06	0.36	0.67	0.72	0.39	-0.09	-0.49	0.35	0.59	-0.4	0.92	0.47	0.36	0.36	0.28	0.74
Property Plant And Equipment Net	0.97	0.94	0.95	0.59	0.93	0.42		-0.44	-0.91	0.89	0.78	0.97	0.9	0.9	0.89	-0.06	0.55	0.93	0.91	0.64	0.59	0.99	0.94	0.95	0.91	0.89
Net Debt	-0.55	-0.27	-0.28	0.2	-0.69	0.42	-0.44		0.17	-0.37	-0.88	-0.5	-0.27	-0.19	-0.58	0.28	-0.87	-0.5	-0.38	-0.86	0.2	-0.37	-0.6	-0.59	-0.66	-0.1
Retained Earnings	-0.8	-0.86	-0.87	-0.6	-0.77	-0.59	-0.91	0.17		-0.93	-0.6	-0.82	-0.8	-0.85	-0.71	-0.27	-0.31	-0.8	-0.9	-0.4	-0.6	-0.93	-0.76	-0.78	-0.72	-0.91
Accounts Payable	0.79	0.81	0.83	0.52	0.81	0.46	0.89	-0.37	-0.93		0.69	0.8	0.75	0.83	0.7	0.13	0.4	0.79	0.96	0.49	0.52	0.92	0.76	0.78	0.72	0.9
Cash	0.85	0.63	0.64	0.13	0.93	-0.06	0.78	-0.88	-0.6	0.69		0.81	0.61	0.55	0.83	-0.1	0.87	0.79	0.69	0.91	0.13	0.73	0.86	0.87	0.9	0.48
Non Current Assets Total	0.99	0.91	0.91	0.57	0.96	0.36	0.97	-0.5	-0.82	0.8	0.81		0.91	0.88	0.94	-0.18	0.61	0.89	0.83	0.69	0.57	0.95	0.96	0.97	0.94	0.81
Non Currrent Assets Other	0.92	0.97	0.96	0.84	0.81	0.67	0.9	-0.27	-0.8	0.75	0.61	0.91		0.97	0.93	-0.33	0.26	0.85	0.87	0.37	0.84	0.9	0.91	0.92	0.88	0.91
Other Assets	0.87	0.94	0.93	0.86	0.78	0.72	0.9	-0.19	-0.85	0.83	0.55	0.88	0.97		0.85	-0.27	0.19	0.79	0.91	0.3	0.86	0.91	0.84	0.86	0.79	0.96
Cash And Short Term Investments	0.97	0.89	0.89	0.62	0.92	0.39	0.89	-0.58	-0.71	0.7	0.83	0.94	0.93	0.85		-0.37	0.55	0.89	0.82	0.63	0.62	0.86	0.99	0.99	0.99	0.75
Common Stock Shares Outstanding	-0.22	-0.18	-0.15	-0.36	-0.14	-0.09	-0.06	0.28	-0.27	0.13	-0.1	-0.18	-0.33	-0.27	-0.37		0.0	-0.08	-0.06	-0.02	-0.36	-0.03	-0.26	-0.26	-0.28	-0.06
Non Current Liabilities Total	0.61	0.31	0.32	-0.29	0.76	-0.49	0.55	-0.87	-0.31	0.4	0.87	0.61	0.26	0.19	0.55	0.0		0.53	0.32	0.99	-0.29	0.48	0.59	0.61	0.65	0.12
Other Current Assets	0.93	0.94	0.94	0.56	0.86	0.35	0.93	-0.5	-0.8	0.79	0.79	0.89	0.85	0.79	0.89	-0.08	0.53		0.86	0.62	0.56	0.92	0.95	0.93	0.93	0.8
Other Stockholder Equity	0.85	0.9	0.92	0.69	0.82	0.59	0.91	-0.38	-0.9	0.96	0.69	0.83	0.87	0.91	0.82	-0.06	0.32	0.86		0.42	0.69	0.93	0.85	0.85	0.81	0.94
Total Liab	0.69	0.42	0.42	-0.18	0.82	-0.4	0.64	-0.86	-0.4	0.49	0.91	0.69	0.37	0.3	0.63	-0.02	0.99	0.62	0.42		-0.18	0.57	0.68	0.69	0.73	0.23
Net Invested Capital	0.58	0.79	0.78	1.0	0.38	0.92	0.59	0.2	-0.6	0.52	0.13	0.57	0.84	0.86	0.62	-0.36	-0.29	0.56	0.69	-0.18		0.63	0.58	0.58	0.51	0.83
Property Plant And Equipment Gross	0.94	0.95	0.96	0.63	0.9	0.47	0.99	-0.37	-0.93	0.92	0.73	0.95	0.9	0.91	0.86	-0.03	0.48	0.92	0.93	0.57	0.63		0.91	0.92	0.87	0.93
Total Current Assets	0.99	0.92	0.92	0.58	0.94	0.36	0.94	-0.6	-0.76	0.76	0.86	0.96	0.91	0.84	0.99	-0.26	0.59	0.95	0.85	0.68	0.58	0.91		1.0	0.99	0.78
Non Current Liabilities Other	1.0	0.92	0.91	0.58	0.96	0.36	0.95	-0.59	-0.78	0.78	0.87	0.97	0.92	0.86	0.99	-0.26	0.61	0.93	0.85	0.69	0.58	0.92	1.0		0.99	0.79
Net Working Capital	0.98	0.88	0.88	0.51	0.95	0.28	0.91	-0.66	-0.72	0.72	0.9	0.94	0.88	0.79	0.99	-0.28	0.65	0.93	0.81	0.73	0.51	0.87	0.99	0.99		0.71
Common Stock	0.81	0.94	0.94	0.83	0.71	0.74	0.89	-0.1	-0.91	0.9	0.48	0.81	0.91	0.96	0.75	-0.06	0.12	0.8	0.94	0.23	0.83	0.93	0.78	0.79	0.71

Click cells to compare fundamentals

Sana Biotechnology Account Relationship Matchups

Sana Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	415.7M	730.3M	1.1B	822.7M	565.3M	677.9M
Other Current Liab	18.0M	21.8M	78.7M	83.9M	47.2M	46.0M
Total Current Liabilities	19.8M	31.5M	99.2M	111.5M	64.5M	60.2M
Total Stockholder Equity	(142.5M)	(421.2M)	728.5M	499.3M	287.5M	172.0M
Other Liab	74.7M	198.9M	199.9M	116.0M	133.4M	129.7M
Net Tangible Assets	(342.4M)	(621.0M)	528.7M	299.5M	344.4M	361.6M
Property Plant And Equipment Net	69.3M	109.9M	161.8M	159.4M	145.6M	118.5M
Net Debt	(31.8M)	(340.1M)	(142.1M)	(68.5M)	(29.4M)	(30.9M)
Retained Earnings	(144.1M)	(429.4M)	(785.4M)	(1.1B)	(1.3B)	(1.3B)
Accounts Payable	0.0	2.3M	2.2M	2.9M	4.1M	2.1M
Cash	80.0M	412.0M	253.0M	176.8M	133.5M	199.1M
Non Current Assets Total	271.4M	345.8M	571.3M	378.3M	351.8M	352.1M
Non Currrent Assets Other	2.3M	2.3M	13.8M	9.0M	6.4M	6.3M
Other Assets	2.3M	2.3M	13.8M	9.0M	10.4M	6.3M
Cash And Short Term Investments	139.0M	412.0M	746.9M	434.0M	205.2M	360.7M
Short Term Investments	59.0M	253.5M	298.0M	247.2M	71.7M	68.1M
Liabilities And Stockholders Equity	415.7M	730.3M	1.1B	822.7M	565.3M	677.9M
Non Current Liabilities Total	538.4M	1.1B	301.7M	211.9M	213.3M	324.1M
Capital Lease Obligations	48.2M	71.9M	110.9M	108.3M	104.1M	81.3M
Other Current Assets	5.3M	12.4M	14.2M	20.5M	8.3M	11.5M
Other Stockholder Equity	(415.8M)	852.9M	1.5B	1.6B	1.6B	941.7M
Total Liab	558.2M	1.2B	400.9M	323.4M	277.8M	367.9M
Net Invested Capital	(142.5M)	(421.2M)	728.5M	499.3M	287.5M	172.0M
Property Plant And Equipment Gross	69.3M	109.9M	180.6M	193.4M	187.4M	135.9M
Total Current Assets	144.3M	384.5M	558.1M	444.4M	213.5M	325.9M
Accumulated Other Comprehensive Income	26K	30K	(1.4M)	(4.3M)	(60K)	(63K)
Capital Stock	1K	2K	18K	19K	20K	11K
Non Current Liabilities Other	74.7M	198.9M	301.7M	211.9M	122.4M	166.8M
Net Working Capital	124.4M	353.0M	458.9M	332.9M	149.0M	265.7M
Property Plant Equipment	68.8M	109.9M	65.5M	66.9M	77.0M	68.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Sana Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sana Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sana Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sana Biotechnology Stock:

How To Invest In Sana

Details

Is Sana Stock a good investment?

Details

What is Sana Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.

You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.40)

Return On Assets

(0.31)

Return On Equity

(0.93)

The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sana Capital Expenditures vs Stock Based Compensation Analysis

Capital Expenditures vs Stock Based Compensation

Capital Expenditures vs Stock Based Compensation Correlation Analysis

Correlation Coefficient

Capital Expenditures

Stock Based Compensation

Sana Biotechnology fundamental ratios Correlations

Sana Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sana Biotechnology fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Other	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Liabilities Other	+ 1.0	Total Current Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Property Plant And Equipment Gross	- 0.93	Retained Earnings
Accounts Payable	- 0.93	Retained Earnings
Common Stock	- 0.91	Retained Earnings
Retained Earnings	- 0.91	Property Plant And Equipment Net
Other Stockholder Equity	- 0.9	Retained Earnings
Cash	- 0.88	Net Debt